CHMP recommends licence extension for conestat alfa (Ruconest)

Following review, the CHMP recommended a licence extension for the use of conestat alfa for acute angioedema attacks in children aged 2 years and above. It is currently licensed for use in this indication for adults and adolescents only.

European Medicines Agency